drugset / Trial / NCT05367960
An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome
NaSingle-groupOpen-labelTreatment
Summary
This is a 4-year, open-label extension (OLE) study for subjects completing one of two double-blind clinical trials with BPN14770, Study BPN14770-CNS-301 (in adult males) and Study BPN14770-CNS-204 (in adolescent males).
Timeline
- Start
- 2022-11-01
- Primary completion
- 2027-09-30
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | zatolmilast | Small molecule | 15 mg | — |
| Subject | zatolmilast | Small molecule | 25 mg | — |